H.I.G.-WHITEHORSE-EUROPE
26.3.2024 14:31:32 CET | Business Wire | Press release
H.I.G. WhiteHorse Europe, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a financing package for Stordata (the “Company”).
Founded in 1988, and headquartered in Versailles, France, Stordata has established itself as a reference partner for the digital transformation of mid-size and large companies, with around 500 clients. An expert in architecture, administration, and maintenance of security and data management systems, particularly in the cloud, the Company provides critical continuous access services to its clients. The services allow clients to leverage their data in a complex and constantly evolving IT environment. The Company has experienced sustained growth in recent years and is developing additional service offerings around cybersecurity and cloud services.
Stordata is embarking on a new chapter in its development through the acquisition of a majority stake by funds advised by Elyan Partners (“Elyan”), a member of the Edmond de Rothschild Private Equity partnership from the founders and executives of the Company, who are reinvesting in the Company.
H.I.G. WhiteHorse Europe has arranged a bespoke financing package, which will be used to finance the acquisition and provide additional capital to support the Company’s expansion, especially through an active buy-and-build strategy.
H.I.G. WhiteHorse Europe, through some of its affiliates, acted as the sole arranger, while Caisse d’Epargne et de Prévoyance Hauts de France participated in the financing alongside H.I.G. WhiteHorse.
Marc Michel, Co-Founder, and Olivier Teichman, CEO of Stordata, said: “Stordata’s success is built on the technical expertise of our employees, the quality of service delivered to our clients, and the trust placed in us by our technology partners. We are so grateful for their continued support. We are also excited by our new partnership with Elyan and appreciative of the confidence we received from H.I.G. WhiteHorse and Caisse d’Epargne et de Prévoyance Hauts de France. We believe Stordata is poised for a robust growth phase.”
Jeremie Melin and Vincent Manes, Partners at Elyan said: “We have been impressed by what Stordata has built over the past years. We are convinced that it can be the foundation of an ambitious growth in France and in Europe, to offer even more value and expertise to Stordata’s clients, particularly in cybersecurity and in the cloud. With H.I.G. WhiteHorse and Caisse d’Epargne et de Prévoyance Hauts de France, we believe we have the right like-minded partners who understand the business and share common values and vision.”
Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said: “Stordata has embarked on a remarkable growth journey in recent years, leveraging its expertise in security and data management, further reinforcing its position in the French digital transformation sector. We are excited to partner with a very experienced investor in Elyan and to contribute to the future success of the Company via a tailor-made financing.”
Charles Bourgeois, Managing Director at H.I.G. WhiteHorse Europe, said: “We are delighted to support Stordata and Elyan. We have been impressed by Stordata’s very high level of expertise and by the quality of its management team. Stordata's strong market reputation and significant market share have firmly established the company as the market leader among mid- and large-size clients.”
About Stordata
Stordata is an independent expert in data and virtualization, combining consulting, transformation management, administration, and maintenance of data security and management systems. Its cloud offering (StorCloud) is ISO27001 and HDS (Hébergeurs de Données de Santé - Health Data Hosts) certified.
About H.I.G. Capital
H.I.G. Capital is a leading global alternative investment firm with $60 billion of capital under management.* Based in Miami, and with offices in Atlanta, Boston, Chicago, Dallas, Los Angeles, New York, and San Francisco in the United States, as well as international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, and Dubai, H.I.G. specializes in providing both debt and equity capital to middle market companies, utilizing a flexible and operationally focused/ value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations, and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche, and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. also manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
- H.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.
Since its founding in 1993, H.I.G. has invested in and managed more than 400 companies worldwide. The Firm’s current portfolio includes more than 100 companies with combined sales in excess of $53 billion. For more information, please refer to the H.I.G. website at hig.com.
About Elyan Partners & ERES IV
Elyan Partners SAS is a financial investment advisor and partner of Edmond de Rothschild Private Equity. Elyan is the exclusive advisor to the ERES funds and an advisor to the Privilege funds of the Edmond de Rothschild Group. Edmond de Rothschild Equity Strategies IV SLP (“ERES IV”) invests in medium-sized companies in Europe and North America.
Edmond de Rothschild Private Equity is the trade name of the Edmond de Rothschild Group’s private equity entities and has over CHF 3.6 billion of assets under management. Founded in 1953, the Group had nearly CHF 158 billion in assets under management as of 31 December 2022, 2,500 employees, and 30 offices worldwide.
*Based on total capital raised by H.I.G. Capital and affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326501486/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
